Intravenous sotalol decreases transthoracic cardioversion energy requirement for chronic atrial fibrillation in humans: Assessment of the electrophysiological effects by biatrial basket electrodes

Journal of the American College of Cardiology

Volumn 35, Issue 6, 2000, Pages 1434-1441

  Lai, Ling Ping ^a   Lin, Jiunn Lee ^a   Lien, Wen Pin ^a   Tseng, Yung Zu ^a   Huang, Shoei K Stephen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

SOTALOL;

ADULT; AGED; ARTICLE; CARDIOVERSION; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATION; DRUG EFFECT; DRUG INFUSION; ELECTRODE; ENERGY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART LEFT ATRIUM; HEART MUSCLE REFRACTORY PERIOD; HEART RIGHT ATRIUM; HUMAN; MALE; PRIORITY JOURNAL; SINUS RHYTHM;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COMBINED MODALITY THERAPY; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; ELECTRODES, IMPLANTED; FEMALE; HEART ATRIA; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PREMEDICATION; RECURRENCE; SOTALOL;

EID: 0034025980     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00597-0     Document Type: Article

References (44)

1. Prystowsky E.N., Benson W., Fuster V., et al. Management of patients with atrial fibrillation. A statement for health care professionals from the subcommittee on electrocardiography and electrophysiology. American Heart Association. Circulation. 93:1996;1262-1277.
2. Nattel S., Hadjis T., Talajic M. The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs. 48:1994;345-371.
3. Dittrich H.C., Erickson J.S., Schneiderman T., Blacky A.R., Savides T., Nicod P.H. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol. 63:1989;193-197.
4. Brode S.E., Schwartzman D., Callans D.J., Gottlieb C.D., Marchlinski F.E. ICD-antiarrhythmic drug and ICD-pacemaker interactions. J Cardiovasc Electrophysiol. 8:1997;830-842.
5. Guarnieri T., Levine J.H., Veltri E.P., et al. Success of chronic defibrillation and the role of antiarrhythmic drugs with the automatic implantable cardioverter/defibrillator. Am J Cardiol. 60:1987;1061-1064.
6. Troup P.J., Chapman P.D., Olinger G.N., Kleinman L.H. The implanted defibrillator relation of defibrillating lead configuration and clinical variables to defibrillation threshold . J Am Coll Cardiol. 6:1985;1315-1321.
7. Dawson A.K., Steinberg M.I., Shapland J.E., et al. Effects of class I and class II drugs on current and energy required for internal defibrillation. Circulation. 72:1985;384.
8. Dorian P., Newman D. Effect of sotalol on ventricular fibrillation and defibrillation in humans. Am J Cardiol. 72:1993;72A-79A.
9. Wang M., Dorian P. D,1- and d-sotalol decrease defibrillation energy requirements. PACE. 12:1989;1522-1529.
10. Echt D.S., Gremillion S.T., Lee J.T., et al. Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices. J Cardiovasc Electrophysiol. 5:1994;752-760.
11. Dorian P., Fain E.S., Davy J.M., Winkle R.A. Lidocaine causes a reversible, concentration dependent increase in defibrillation energy requirements. J Am Coll Cardiol. 8:1986;327-332.
12. Fain E.S., Dorian P., Davy J.M., Kates R.E., Winkle R.A. Effects of encainide and its metabolites on energy requirements for defibrillation. Circulation. 73:1986;1334-1341.
13. Jones D.L., Klein G.J., Guiraudon G.M., et al. Effects of lidocaine and verapamil on defibrillation in humans. J Electrocardiol. 24:1991;299-305.
14. Murakawa Y., Inoue H., Kuo T.T., et al. Prolongation of intraventricular conduction time associated with fatal impairment of defibrillation efficiency during treatment with class I antiarrhythmic agents. J Cardiovasc Pharmacol. 25:1995;194-199.
15. Hernandez R., Mann D.E., Breckinridge S., et al. Effects of flecainide on defibrillation thresholds in the anesthetized dog. J Am Coll Cardiol. 14:1989;777-781.
16. Jung W., Manz M., Pizzulli L., et al. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol. 70:1992;1023-1027.
17. Fogoros R.N. Amiodarone-induced refractoriness to cardioversion. Ann Intern Med. 100:1984;699-700.
18. Echt D.S., Black J.N., Barbey J.J., et al. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs sodium channel block and action potential prolongation . Circulation. 79:1989;1106-1117.
19. Wesley R.C. Jr, Farkhani F., Morgan D., et al. Ibutilide enhanced defibrillation via plateau sodium current activation . Am J Physiol. 264:1993;H1269-H1274.
20. Labhasetwar V., Underwood T., Heil R.W. Jr, et al. Epicardial administration of ibutilide from polyurethane matrices effects on defibrillation threshold and electrophysiologic parameters . J Cardiovasc Pharmacol. 24:1994;826-840.
21. Beatch G.N., Dickenson D.R., Davis D.R., et al. Dofetilide relationship between refractory period extension and defibrillation threshold . PACE. 18:1995;820.
22. Rossi M., Lown B. The use of quinidine in cardioversion. Am J Cardiol. 19:1967;234-238.
23. Hillestad L., Dale J., Storstein O. Quinidine before direct current countershock. A controlled study. Br Heart J. 34:1972;139-142.
24. Sodermark T., Jonsson B., Olsson A., et al. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicenter study from Stockholm. Br Heart J. 37:1975;486-492.
25. Jacobs L.O., Andrew T.C., Pederson D.N., Donovan D.J. Effect of intravenous procainamide on direct-current cardioversion of atrial fibrillation. Am J Cardiol. 82:1998;241-242.
26. Guarnieri T., Tomaselli G., Griffith L.S.C., Brinker J. The interaction of antiarrhythmic drugs and the energy for cardioversion of chronic atrial fibrillation. PACE. 14:1991;1007-1012.
27. Van Gelder I.C., Crijns H.J.G.M., Van Gilst W.H., De Langen C.D.J., Van Wijk L.M., Lie K.I. Effects of flecainide on the atrial defibrillation threshold. Am J Cardiol. 63:1989;112-114.
28. Oral H., Souza J.J., Michaud G.F., et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med. 340:1999;1849-1854.
29. Iskos D., Lurie K.G., Adler S.W., et al. Effect of parenteral d-sotalol on transvenous atrial defibrillation threshold in a canine model of atrial fibrillation. Am Heart J. 132:1996;116-119.
30. Lau C.P., Lok N.S. A comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold. PACE. 20:1997;2442-2452.
31. Kim K.B., Rodefeld M.D., Schuessler R.B., Cox J.L., Boineau J.P. Relationship between local atrial fibrillation interval and refractory period in the isolated canine atrium. Circulation. 94:1996;2961-2967.
32. Lammers W.J.E.P., Allesie M.A., Rensma P.L., Schalij M.J. The use of fibrillation cycle length to determine spatial dispersion in electrophysiological properties and to characterize the underlying mechanism of fibrillation. New Trends Arrhythmias. 2:1986;109-112.
33. Antonaccio M.J., Gomoll A. Pharmacology, pharmacodynamics and pharmacokinetics of sotalol. Am J Cardiol. 65:1990;12A-21A.
34. Moe G.K. On the multiple wavelet hypothesis of atrial fibrillation. Arch Int Pharmacodyn Ther. 140:1962;183-188.
35. Moe G.K., Rheinboldt W.C., Abildskov J.A. A computer model of atrial fibrillation. Am Heart J. 67:1964;200-220.
36. Misier A.R.R., Opthof T., Hemel N.M., et al. Increased dispersion of "refractoriness" in patients with idiopathic paroxysmal atrial fibrillation. J Am Coll Cardiol. 19:1992;1531-1535.
37. Cosio F.G., Palacios J., Vidal J.M., Cocina E.G., Gomez-Sanchez M.A., Tamargo L. Electrophysiologic studies in atrial fibrillation slow conduction of premature impulses, a possible manifestation of the background for reentry . Am J Cardiol. 51:1983;122-136.
38. Capucci A., Biffi M., Boriani G., et al. Dynamic electrophysiological behavior of human atrial fibrillation. Circulation. 92:1995;1193-1202.
39. Nattel S., Bourne G., Talajic M. Insights into mechanisms of antiarrhythmic drug action from experimental models of atrial fibrillation. J Cardiovasc Electrophysiol. 8:1997;469-480.
40. Satoh T., Zipes D.P. Unequal atrial stretch in dogs increases dispersion of refractoriness conducive to developing atrial fibrillation. J Cardiovasc Electrophysiol. 7:1996;833-842.
41. Rattes M.F., Sharma G.J., Szabo T., Jones D.L. Adrenergic effects on internal cardiac defibrillation threshold. Am J Physiol. 22:1987;H500-H506.
42. Ruffy R., Schechtman K., Monje E. Beta-adrenergic modulation of direct defibrillation energy in anesthetized dog heart. Am J Physiol. 17:1985;H674-H677.
43. Levy S., Lauribe P., Dolla E., et al. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation. 86:1992;1415-1420.
44. Schmitt C., Ait E., Plewan A., et al. Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation. J Am Coll Cardiol. 28:1996;994-999.